胸部放疗剂量在局限期小细胞肺癌治疗中的作用:基于美国国家癌症数据库的研究
该研究基于美国国家癌症数据库2004至2015年2261例接受根治性同步放化疗的局限期小细胞肺癌患者,比较超分割每日两次1.5 Gy(HF1.5)与常规分割每日一次1.8 Gy(SF1.8)或2.0 Gy(SF2.0)的生存差异。全部期别中位总生存HF1.5组21.6个月、SF1.8组18.9个月、SF2.0组19.4个月(log-rank P = .0079)。多因素分析显示SF1.8(HR = 1.30,1.03-1.63)和SF2.0(HR = 1.20,1.00-1.45)与较差的1年生存相关。
要点
- 全部期别中位总生存:HF1.5组21.6个月 vs SF1.8组18.9个月 vs SF2.0组19.4个月(log-rank P = .0079)。
- 多因素分析示SF1.8(HR = 1.30,1.03-1.63)和SF2.0(HR = 1.20,1.00-1.45)与较差的1年生存相关。
- 分层分析示显著关联局限于男性或黑人、年龄>65岁、1种合并症、等待放疗>60天或学术医疗中心治疗者。
核心结论
- 真实世界治疗结局分析显示,与常规每日一次分割方案相比,接受超分割每日两次放疗与局限期小细胞肺癌患者诊断后1年生存改善相关,尤其在部分亚组患者中。
- 部分关联在诊断后3年仍保留统计学显著性。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入2004至2015年接受根治性放疗(分次剂量1.5、1.8或2.0 Gy)同步化疗的2261例局限期小细胞肺癌患者。
- 采用Kaplan-Meier法评估总生存,Cox比例风险回归分析超分割每日两次1.5 Gy(HF1.5)与每日一次1.8 Gy(SF1.8)或2.0 Gy(SF2.0)的生存差异。
- 按年龄、性别、种族、放疗等待时间、机构类型和Charlson合并症指数进行亚组分析。
主要发现
- 全部期别中位总生存HF1.5组21.6个月、SF1.8组18.9个月、SF2.0组19.4个月(log-rank P = .0079)。
- 多因素分析调整人口学因素、社会经济状态、肿瘤特征和诊断年份后,与HF1.5相比,SF1.8(HR = 1.30,1.03-1.63)和SF2.0(HR = 1.20,1.00-1.45)与较差的1年生存相关。
- 该关联在IIb期至III期患者中比I期至IIa期患者更明显。
- 倾向评分加权分析显示相似结果。
- 分层分析显示显著关联局限于男性或黑人患者、年龄>65岁、有1种合并症、等待放疗>60天或于学术医疗中心治疗者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Small cell lung cancer (SCLC) is a highly fatal disease, but its treatment has remained relatively unchanged for decades. Randomized clinical trials evaluating radiation therapy (RT) dosing and fractionation have yielded mixed results on overall survival (OS). METHODS AND MATERIALS: We identified 2261 patients with limited-stage (LS) SCLC undergoing definitive RT at 1.5, 1.8, and 2.0 Gy dose per fraction, concurrently with chemotherapy, between 2004 and 2015 within the National Cancer Database. Overall survival (OS) was evaluated using the Kaplan-Meier method, and Cox proportional hazards regression was used to investigate whether there was any survival difference among patients who received hyperfractionated, twice-daily RT at 1.5 Gy per fraction (HF1.5) and once-daily, standard fractionation RT at 1.8 Gy (SF1.8) or 2.0 Gy (SF2.0) per fraction. Subgroup analyses by age, sex, race, time to RT, facility type, and Charlson comorbidity index were also performed. RESULTS: All stage median OS rates for HF1.5, SF1.8, and SF2.0 Gy groups were 21.6, 18.9, and 19.4 months, respectively (log-rank P = .0079). Multivariate analyses adjusting for demographic factors, socioeconomic status, tumor characteristics, and year of diagnosis showed SF1.8 (hazard ratio [HR] = 1.30, 1.03-1.63) and SF2.0 (HR = 1.20, 1.00-1.45) was associated with worse 1-year survival compared with HF1.5. This association was more evident in stage IIb-stage III than stage I to stage IIa patients. Propensity score-weighted analysis showed similar results. Stratified analyses showed the significant associations were confined to male or black patients, those aged >65 years, with 1 comorbidity, who had waited >60 days to start RT or were treated at an academic medical center. CONCLUSIONS: Analyses of real-world treatment outcome data showed that receiving hyperfractionated, twice-daily RT was associated with improved survival among patients with LS-SCLC compared with standard, once-daily fractionation regimens at 1 year after diagnosis, particularly for subsets of patients. Some associations retained statistical significance 3 years postdiagnosis.
引用
- Shidal C, Osmundson EC, Cui Y, et al. The Role of Thoracic Radiation Therapy Dosing in the Treatment of Limited-Stage Small Cell Lung Cancer: A Study Based on the National Cancer Database. Adv Radiat Oncol. 2022. PMID: 35469183. doi:10.1016/j.adro.2022.100907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。